Mediation of 5G Effects on Sleep5G Cav12 SleepNCT06998368
A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans
A study testing Nimodipine Capsules and 5G RF-EMF in people with Mediation of 5G Effects on Sleep, run by Hans-Peter Landolt at 1 site in Switzerland.
Trial summary
Electromagnetic fields (EMFs) generated by the use of 5G technology influence certain sleep characteristics, especially in individuals carrying a specific genetic variant of a protein in the brain that regulates the activity of nerve cells. Read more about this study
- Who is it for?
- Ages 20 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Mediation of 5G Effects on Sleep
- What is being tested?
- Nimodipine Capsules and 5G RF-EMF
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteSwitzerland
- Study dates
- 22 Oct 2024to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- For the first part of the study (genotyping and questionnaires):
- Age: 20-40 years old.
- German and/or English language skills (reading and writing)
- Informed Consent as documented by signature
- For the second and third party of the study:
- Completion of the first part of the present study or of the precursor study (BASEC-ID: 2016-02049)
Show all 14Show fewer
- CACNA1C rs7304986 T/C allele-carrier
- Male gender
- Female gender if using hormonal contraception for the duration of the study (e.g., pill as combination/single preparation, three-month injection, hormonal IUD, hormonal implant, hormonal patch)
- Right-handedness
- Body Mass Index (BMI): BMI comprised between 17.0 kg/m2 and 26.0 kg/m2
- Moderate alcohol consumption (less than 5 reported alcoholic drinks per week)
- Moderate caffeine consumption (less than 3 reported caffeinated beverage or food products per day such as cola, coffee, energy drinks, green and black tea, chocolate)
- Informed Consent as documented by signature.
Who cannot join
- For the second and third party of the study:
- Travel with a time difference of more than 2 time zones in the last 30 days before study entry or during the study period
- Shift work at night
- Extreme chronotype or duration of sleep (5 hours < reported habitual sleep duration per night > 10 hours)
- Known sleep disorders or diseases
- Serious acute or chronic neurological, mental, or general medical conditions that, in the opinion of the investigator, may pose a risk to participation or affect study measurements
Show all 21Show fewer
- Use of medications (regularly or during the study period) that, in the opinion of the investigator, may affect study measurements.
- Use of illegal drugs
- Smoking (or other tobacco use)
- Known or suspected non-compliance with the investigators' indications
- Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
- Severe skin allergies or hypersensitivities
- Participation in another clinical trial in the last 30 days prior to inclusion or during the present study
- Contraindications to nimodipine, e.g., known hypersensitivity or allergy to nimodipine or any of the excipients
- Other cases in which the use of nimodipine is discouraged according to the summary of product characteristics (SPC)
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases (Note: Female participants who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential)
- Sleep apnea and nocturnal myoclonus index of ≥ 5 per hour of sleep (as assessed during the screening night)
- Sleep efficiency < 80% (as assessed during the screening night)
- Other relevant findings in the screening/adaptation night (e.g., indications of sleep disorders), which in the opinion of the investigator may pose a risk for participation or influence the study measurements.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University of Zurich, Institute of Pharmacology and Toxicology
Zurich, Canton of Zurich, 8057
Rachele Maria D'Angelo, M. Sc., +41 44 635 59 61, rachele.dangelo@pharma.uzh.ch
Hans-Peter Landolt, Prof. Dr. sc. nat., +41 44 635 59 53, landolt@pharma.uzh.ch
About this study
Electromagnetic fields (EMFs) generated by the use of 5G technology influence certain sleep characteristics, especially in individuals carrying a specific genetic variant of a protein in the brain that regulates the activity of nerve cells. This protein is a voltage-gated calcium channel called CaV1.2 and could be involved in the effects of 5G technology on sleep. The calcium channel CaV1.2 can be selectively blocked by the drug nimodipine.
To demonstrate that CaV1.2 is indeed involved in the effects of 5G technology on sleep, the researchers are investigating in this study, with healthy subjects carrying the sought-after genetic variant, whether the administration of nimodipine and thus the blockade of the calcium channel before exposure mitigates or eliminates the effects of EMF on sleep health.
Read the detailed description
This study tests a causal role of voltage-gated CaV1.2 calcium channels in mediating the effects of a 5G electromagnetic field on sleep-related brain health in humans.
The study comprises a large-scale genetic screening in order to select the allele-carriers, a sleep screening night, and four experimental nights where participants are exposed to either an active 5G field or sham, combined with either nimodipine (which is a brain-penetrant L-type calcium channel blocker) or placebo. Participants will undergo polysomnographic recordings, high-density electroencephalography (EEG) during wake, peripheral measurements, cognitive and neuropsychiatric assessments.
- Conditions
- Mediation of 5G Effects on Sleep
- Being tested
- Nimodipine Capsules, 5G RF-EMF
- Keywords
- 5G, CACNA1C, CaV1.2, electromagnetic, EMF, nimodipine, RF-EMF, sleep, rs7304986, voltage-gated calcium channel, brain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nimodipine CapsulesDrug
Two times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding.
5G RF-EMFRadiation
Participants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency [TDD] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design.
| Study group | Role | What they receive |
|---|---|---|
| Arm2 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm1 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining eighteen sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm3 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm4 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm6 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm7 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm8 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm9 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm10 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm11 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm12 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm5 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm13 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm14 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm15 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm16 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm17 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm18 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm19 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm20 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm21 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm22 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm23 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
| Arm24 | Other | The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. Receives: Drug: Nimodipine Capsules; Radiation: 5G RF-EMF |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sleep spindle center frequency
In previous research, the investigators detected a positive shift in the sleep spindle center frequency (during NREM sleep phase) after 30-min pre-sleep exposure to a 5G signal at 3600 MHz, 100 MHz bandwidth in heterozygous T/C allele-carriers (rs7304986) compared to sham.
The sleep spindle center frequency is a parameter that can be extracted from the overnight electroencephalographic recordings.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Secondary outcomes (49)
Sex distribution of participants
Self-reported biological sex (male or female) is recorded during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Age of Participants
Age is recorded in years based on the year of birth provided during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Pregnancy status
Female participants report current pregnancy status during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
EEG power spectra during Non-Rapid-Eye-Movement (NREM) sleep
Power spectra will be computed from artifact-free EEG data recorded during NREM sleep. Spectral power (µV²/Hz) will be computed in standard frequency bands.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Total sleep time
Sleep electroencephalographic data allow to extract total sleep time (min) (total amount of time spent asleep)
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Neurocognitive performance as assessed in the psychomotor vigilance task (PVT)
The PVT is administered before and after sleep at each experimental night and provides a score reflecting sustained or vigilant attention performance.
Measured: Assessed on each of the four experimental nights, pre- and post-sleep
Heart rate
Heart rate (bpm) is extracted from electrocardiographic recording during exposure and from polysomnographic overnight recordings
Measured: Assessed on each of the four experimental nights, from electrocardiographic recordings during pre-sleep exposure and polysomnographic overnight recordings
Handedness of participants
Participants report their handedness (right-handed or left-handed) during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
BMI of participants
Self-reported height (in centimeters) and weight (in kilograms) of participants is reported during the large-scale genetic screening (first study part) via an online questionnaire. From Height and Weight, BMI is calculated.
Measured: At the large-scale genetic screening
Highest level of education of participants
The highest level of education of participants (elementary school, professional school, high school, university of applied sciences and arts, or university) is self-reported during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Phone call time
Participants report their phone call time without headphones (Not at all, Less than 1 hour per week, 1-2 hours per week or more than 2 hours per week) during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Caffeine consumption
Participants report their caffeine consumption (None, 1-2 caffeinated foods or beverages per day, 3-5 caffeinated foods or beverages per day or More than 5 caffeinated foods or beverages per day) during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Alcohol consumption
Participants report their alcohol consumption (None, Less than 1 glass per week, 1-2 glasses per week, 3-5 glasses per week or More than 5 glasses per week) during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Electrohypersensitivity (EHS) status
Participants report their EHS status during the large-scale genetic screening (first study part) via filling out the online questionnaire by M. Röösli, E. Mohler, and P. Frei (2010).
Measured: At the large-scale genetic screening
Sleep disturbances
The presence of sleep disturbances is self-reported by participants during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Comorbidities
Participants self-report the presence of comorbidities during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Night-shift work
Participants report if they engage in night shift work during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Use of medications
Self-reported use of medication is recorded during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Use of illegal drugs
Self-reported use of illegal drugs is recorded during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Use of tobacco products
Use of tobacco products is reported during the large-scale genetic screening (first study part) via an online questionnaire.
Measured: At the large-scale genetic screening
Subjective sleep quality
Participants report about their subjective sleep quality during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index" (high global PSQI score indicates poor sleep quality).
Measured: At the large-scale genetic screening
Daytime sleepiness
Participants report about their daytime sleepiness during the large-scale genetic screening (first study part) via filling out the online questionnaire "Epworth Sleepiness Scale " (high ESS score indicates high daytime sleepiness).
Measured: At the large-scale genetic screening
Diurnal preference
Participants report about their diurnal preference during the large-scale genetic screening (first study part) via filling out the online questionnaire "Munich Chronotype Questionnaire" (if the mid-sleep time on the MCTQ is earlier than 04:00, the participant is considered as preferential morning type, otherwise as preferential evening type).
Measured: At the large-scale genetic screening
Habitual bedtime
Participants report about their subjective habitual bedtime (hh:mm) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Measured: At the large-scale genetic screening
Habitual rise time
Participants report about their subjective habitual rise time (hh:mm) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Measured: At the large-scale genetic screening
Reported time to fall asleep
Participants report about their subjective time to fall asleep (min) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Measured: At the large-scale genetic screening
Reported sleep duration
Participants report about their subjective sleep duration (h:mm) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Measured: At the large-scale genetic screening
Positive and Negative Affect Schedule
Participants report about positive and negative feelings (over the last 12 months) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Positive and Negative Affect Schedule".
Measured: At the large-scale genetic screening
Nocturnal mentation
Participants report about their nocturnal mentation during the large-scale genetic screening (first study part) via filling out online the "Dream Thought Questionnaire".
Measured: At the large-scale genetic screening
Depressive tendency
Participants report about their depressive-like symptoms (experienced in the last 2 weeks) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Beck Depression Index II (BDI-II)".
Measured: At the large-scale genetic screening
Mental suggestibility tendency
Participants report about their mental suggestibility tendency during the large-scale genetic screening (first study part) via filling out the online questionnaire "Short Suggestibility Scale".
Measured: At the large-scale genetic screening
Schizotypal tendency
Participants report about their schizotypal tendencies during the large-scale genetic screening (first study part) via filling out an online adaptation of the questionnaire "Magical Ideation Scale (MIS)".
Measured: At the large-scale genetic screening
ADHD tendency
Participants report about their ADHD-like symptoms during the large-scale genetic screening (first study part) via filling out the online questionnaire "Adult ADHD Self-Report Scale v1.1 (ASRS)".
Measured: At the large-scale genetic screening
EEG power spectra during wakefulness
Power spectra will be computed from artifact-free EEG data recorded during wakefulness. Spectral power (µV²/Hz) will be computed in standard frequency bands.
Measured: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
EEG power spectra during Rapid Eye Movement (REM) sleep
Power spectra will be computed from artifact-free EEG data recorded during REM sleep. Spectral power (µV²/Hz) will be computed in standard frequency bands.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during NREM sleep
The NREM sleep power spectra will be used to extract and parametrize the aperiodic component.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during REM sleep
The REM sleep power spectra will be used to extract and parametrize the aperiodic component.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during wakefulness
The wake power spectra will be used to extract and parametrize the aperiodic component.
Measured: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
Periodic component of the EEG power spectrum during NREM sleep
Gaussian peaks detected in the NREM sleep power spectrum will be used to extract the periodic components, including center frequency, power, and bandwidth.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Periodic component of the EEG power spectrum during REM sleep
Gaussian peaks detected in the REM sleep power spectrum will be used to extract the periodic components, including center frequency, power, and bandwidth.
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions.
Periodic component of the EEG power spectrum during wakefulness
Gaussian peaks detected in the wake power spectrum will be used to extract the periodic components, including center frequency, power, and bandwidth.
Measured: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
Sleep efficiency
Sleep electroencephalographic data allow to extract sleep efficiency (%) ((total sleep time/time in bed) * 100)
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Sleep latency
Sleep electroencephalographic data allow to extract sleep latency (time between lights-off and first occurrence of NREM sleep stage N2).
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions.
Wakefulness after sleep onset
Sleep electroencephalographic data allow to extract WASO (min) (wakefulness after sleep onset).
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Time spent in the different sleep stages
Sleep electroencelographic data allow to calculate the time (min) spent in each sleep substage (NREM1, NREM2, NREM3, REM).
Measured: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Neurocognitive performance as assessed in the sequential finger tapping task (FTT)
The FTT is administered before and after sleep at each experimental night and provides a score reflecting procedural memory and learning performance.
Measured: Assessed on each of the four experimental nights, pre- and post-sleep
Neurocognitive performance as assessed in the visuospatial 2D Object Location Task (OLT)
The OLT is administered before and after sleep at each experimental night and provides a score reflecting declarative memory and learning performance.
Measured: Assessed on each of the four experimental nights, pre- and post-sleep
Heart rate variability
Heart rate variability is extracted from electrocardiographic recording during exposure and from polysomnographic overnight recordings.
Measured: Assessed on each of the four experimental nights, from electrocardiographic recordings during pre-sleep exposure and polysomnographic overnight recordings
Pupil size
Pupil size variation is recorded during exposure.
Measured: Assessed on each of the four experimental nights, from pupillometry recordings during pre-sleep exposure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2025
- Study start22 Oct 2024
- Primary completionJun 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mediation of 5G Effects on SleepStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Each participant of the sleep study will undergo 4 experimental night recordings. On each of the experimental nights, one unique combination of two different interventions will be applied: active exposure to 5G RF-EMF or sham and administration of nimodipine (i.e. verum) or placebo. The four combinations will be: * placebo + sham exposure * placebo + active exposure * verum + sham exposure * verum + active exposure. The sequence order of the 4 nights conditions will be randomized.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hans-Peter Landolt
- Sponsor type
- University, hospital or other
- Collaborators
- Federal Office for the Environment, Switzerland
- Responsible party
- Sponsor-investigator, Hans-Peter Landolt, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06998368
- Sponsor's protocol ID
- 5G-Cav1.2 Sleep
- Acronym
- 5G Cav12 Sleep
- Status last verified
- May 2025
- First submitted
- 23 Apr 2025
- Last updated
- 31 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Any disclosure of information to individuals not directly involved in the study must be approved by the owner of the data.
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans
- ClinicalTrials.gov ID
- NCT06998368
- Acronym / sponsor ID
- 5G Cav12 Sleep / 5G-Cav1.2 Sleep
- Conditions
- Mediation of 5G Effects on Sleep
- Keywords
- 5G, CACNA1C, CaV1.2, electromagnetic, EMF, nimodipine, RF-EMF, sleep
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Hans-Peter LandoltUniversity, hospital or other
- Collaborators
- Federal Office for the Environment, Switzerland
- Study start
- 22 Oct 2024 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 31 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Electromagnetic fields (EMFs) generated by the use of 5G technology influence certain sleep characteristics, especially in individuals carrying a specific genetic variant of a protein in the brain that regulates the activity of nerve cells. This protein is a voltage-gated calcium channel called CaV1.2 and could be involved in the effects of 5G technology on sleep. The calcium channel CaV1.2 can be selectively blocked by the drug nimodipine.
To demonstrate that CaV1.2 is indeed involved in the effects of 5G technology on sleep, the researchers are investigating in this study, with healthy subjects carrying the sought-after genetic variant, whether the administration of nimodipine and thus the blockade of the calcium channel before exposure mitigates or eliminates the effects of EMF on sleep health.
Detailed description
This study tests a causal role of voltage-gated CaV1.2 calcium channels in mediating the effects of a 5G electromagnetic field on sleep-related brain health in humans.
The study comprises a large-scale genetic screening in order to select the allele-carriers, a sleep screening night, and four experimental nights where participants are exposed to either an active 5G field or sham, combined with either nimodipine (which is a brain-penetrant L-type calcium channel blocker) or placebo. Participants will undergo polysomnographic recordings, high-density electroencephalography (EEG) during wake, peripheral measurements, cognitive and neuropsychiatric assessments.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 24
- Model description
- Each participant of the sleep study will undergo 4 experimental night recordings. On each of the experimental nights, one unique combination of two different interventions will be applied: active exposure to 5G RF-EMF or sham and administration of nimodipine (i.e. verum) or placebo. The four combinations will be: * placebo + sham exposure * placebo + active exposure * verum + sham exposure * verum + active exposure. The sequence order of the 4 nights conditions will be randomized.
| Arm | Type | Receives |
|---|---|---|
| Arm2 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm1 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining eighteen sequences will be assigned to one participant each. |
| Arm3 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm4 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm6 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm7 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm8 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm9 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm10 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm11 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm12 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm5 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm13 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm14 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm15 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm16 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm17 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm18 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm19 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm20 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm21 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm22 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm23 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
| Arm24 | Other | Drug: Nimodipine Capsules, Radiation: 5G RF-EMFThe study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Age: 20-40 years old.
- German and/or English language skills (reading and writing)
- Informed Consent as documented by signature
- Completion of the first part of the present study or of the precursor study (BASEC-ID: 2016-02049)
- CACNA1C rs7304986 T/C allele-carrier
Key exclusion criteria (21 listed)
- Travel with a time difference of more than 2 time zones in the last 30 days before study entry or during the study period
- Shift work at night
- Extreme chronotype or duration of sleep (5 hours < reported habitual sleep duration per night > 10 hours)
- Known sleep disorders or diseases
- Serious acute or chronic neurological, mental, or general medical conditions that, in the opinion of the investigator, may pose a risk to participation or affect study measurements
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nimodipine CapsulesTwo times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding. | Drug | Arm1, Arm10, Arm11, Arm12, Arm13, Arm14, Arm15, Arm16, Arm17, Arm18, Arm19, Arm2, Arm20, Arm21, Arm22, Arm23, Arm24, Arm3, Arm4, Arm5, Arm6, Arm7, Arm8, Arm9 |
| 5G RF-EMFParticipants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency [TDD] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design. | Radiation | Arm1, Arm10, Arm11, Arm12, Arm13, Arm14, Arm15, Arm16, Arm17, Arm18, Arm19, Arm2, Arm20, Arm21, Arm22, Arm23, Arm24, Arm3, Arm4, Arm5, Arm6, Arm7, Arm8, Arm9 |
Primary outcome
Sleep spindle center frequency
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
In previous research, the investigators detected a positive shift in the sleep spindle center frequency (during NREM sleep phase) after 30-min pre-sleep exposure to a 5G signal at 3600 MHz, 100 MHz bandwidth in heterozygous T/C allele-carriers (rs7304986) compared to sham. The sleep spindle center frequency is a parameter that can be extracted from the overnight electroencephalographic recordings.
49 secondary outcomes
Sex distribution of participants
Time frame: At the large-scale genetic screening
Age of Participants
Time frame: At the large-scale genetic screening
Pregnancy status
Time frame: At the large-scale genetic screening
EEG power spectra during Non-Rapid-Eye-Movement (NREM) sleep
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Total sleep time
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Neurocognitive performance as assessed in the psychomotor vigilance task (PVT)
Time frame: Assessed on each of the four experimental nights, pre- and post-sleep
Heart rate
Time frame: Assessed on each of the four experimental nights, from electrocardiographic recordings during pre-sleep exposure and polysomnographic overnight recordings
Handedness of participants
Time frame: At the large-scale genetic screening
BMI of participants
Time frame: At the large-scale genetic screening
Highest level of education of participants
Time frame: At the large-scale genetic screening
Phone call time
Time frame: At the large-scale genetic screening
Caffeine consumption
Time frame: At the large-scale genetic screening
Alcohol consumption
Time frame: At the large-scale genetic screening
Electrohypersensitivity (EHS) status
Time frame: At the large-scale genetic screening
Sleep disturbances
Time frame: At the large-scale genetic screening
Comorbidities
Time frame: At the large-scale genetic screening
Night-shift work
Time frame: At the large-scale genetic screening
Use of medications
Time frame: At the large-scale genetic screening
Use of illegal drugs
Time frame: At the large-scale genetic screening
Use of tobacco products
Time frame: At the large-scale genetic screening
Subjective sleep quality
Time frame: At the large-scale genetic screening
Daytime sleepiness
Time frame: At the large-scale genetic screening
Diurnal preference
Time frame: At the large-scale genetic screening
Habitual bedtime
Time frame: At the large-scale genetic screening
Habitual rise time
Time frame: At the large-scale genetic screening
Reported time to fall asleep
Time frame: At the large-scale genetic screening
Reported sleep duration
Time frame: At the large-scale genetic screening
Positive and Negative Affect Schedule
Time frame: At the large-scale genetic screening
Nocturnal mentation
Time frame: At the large-scale genetic screening
Depressive tendency
Time frame: At the large-scale genetic screening
Mental suggestibility tendency
Time frame: At the large-scale genetic screening
Schizotypal tendency
Time frame: At the large-scale genetic screening
ADHD tendency
Time frame: At the large-scale genetic screening
EEG power spectra during wakefulness
Time frame: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
EEG power spectra during Rapid Eye Movement (REM) sleep
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during NREM sleep
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during REM sleep
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during wakefulness
Time frame: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
Periodic component of the EEG power spectrum during NREM sleep
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Periodic component of the EEG power spectrum during REM sleep
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2025.
- Pre-print of our previous research project, providing the background for the current studyLink provided by the sponsor.
- Individual participant dataSharing planned: No. Any disclosure of information to individuals not directly involved in the study must be approved by the owner of the data.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
University of Zurich, Institute of Pharmacology and Toxicology
Zurich, Switzerland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nimodipine Capsules and 5G RF-EMF in people with Mediation of 5G Effects on Sleep, run by Hans-Peter Landolt at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sleep spindle center frequency (time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2025.